Larimar Therapeutics
LRMR
51 hedge funds and large institutions have $17M invested in Larimar Therapeutics in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 27 closing their positions.
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
9.37% less ownership
Funds ownership: 70.85% → 61.49% (-9.4%)
28% less funds holding
Funds holding: 71 → 51 (-20)
48% less capital inflows, than outflows
Capital inflows: $5.8M | Capital outflows: $11.1M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
74% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.78M |
| 2 |
Morgan Stanley
New York
|
+$1.41M |
| 3 |
6CM
683 Capital Management
New York
|
+$910K |
| 4 |
Renaissance Technologies
New York
|
+$468K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.63M |
| 2 |
AC
Armistice Capital
New York
|
-$2.59M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.16M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.02M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$522K |
LRMR Hedge Fund Activity: Q3 2019 in Review
51 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2019, worth a combined $17M — down 46% from $31.5M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of LRMR and 7 opened new positions — a net loss of 20 holders — while 16 trimmed existing stakes and 15 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $1.78M. The largest seller was Great Point Partners, exiting entirely with an estimated $2.63M sold.
- 51 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2019, down from 71 in Q2 2019.
- Funds reported $17M of Larimar Therapeutics stock for Q3 2019, down 46% quarter-over-quarter.
- 7 funds opened new Larimar Therapeutics positions in Q3 2019 and 27 closed out, a net change of -20 holders.
- The largest Larimar Therapeutics buyer in Q3 2019 was EcoR1 Capital, an estimated $1.78M added.
- The largest Larimar Therapeutics seller in Q3 2019 was Great Point Partners, an estimated $2.63M sold.
Based on aggregated 13F filings for Q3 2019.